Glenmark Pharmaceuticals Ltd reaffirms its commitment to sustainability by joining the esteemed Science Based Targets initiative business ambition for well below 2°C.
Glenmark Pharmaceuticals Ltd has received final approval by the US FDA for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, the generic version of Compazine® Tablets, 5 mg and 10 mg, of GlaxoSmithKline.
Glenmark Specialty SA, has received acceptance from the U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2, first-in-human, clinical study of GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas.
Glenmark Pharmaceuticals Limited has received final approval by the United States Food & Drug Administration for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg.
Glenmark Pharmaceuticals Inc., USA has received a 2nd tentative approval by the USFDA for Saxagliptin Tablets, 2.5 mg and 5 mg, the generic version of Onglyza® Tablets, 2.5 mg and 5 mg, of AstraZeneca AB.
Due to medical necessity and potential drug shortage expectations, the US FDA has provided an exception which enables the Company to supply Atovaquone Oral Suspension USP 750mg/5 to the US market.
Glenmark Pharmaceuticals Ltd is the first to launch in India a unique I.V. injection formulation, AKYNZEO® I.V., for the prevention of CINV, under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.
Glenmark Pharmaceuticals Ltd. to divest select brands and sub-brands from its dermatology segment, for India and Nepal territories, to Eris Oaknet Healthcare Private Limited.
Glenmark Pharmaceuticals Inc., USA has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex® Injection.
Glenmark Pharmaceuticals Limited, an innovation-driven, global pharmaceutical company has launched the first triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India.